Executive Summary B cell protein factory represents a new paradigm for biologics delivery Through HSPC gene editing , B cells can be engineered to continuously secrete antibodies or therapeutic proteins The system is boostable, long-term, and capable of multi-protein output This signals a shift in cell therapy—from “killing cells” to “producing proteins” Companies like Be Biopharma and Immusoft are already moving in this direction Introduction: Are We Redefining Biologics?
